Production (Stage)
Atea Pharmaceuticals, Inc.
AVIR
$2.90
$0.051.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -84.30% | 9.98% | |||
| Gross Profit | 84.30% | -9.98% | |||
| SG&A Expenses | -29.19% | 20.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.70% | 13.89% | |||
| Operating Income | -10.70% | -13.89% | |||
| Income Before Tax | -2.25% | -7.74% | |||
| Income Tax Expenses | -9.78% | -0.44% | |||
| Earnings from Continuing Operations | -2.17% | -7.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.17% | -7.68% | |||
| EBIT | -10.70% | -13.89% | |||
| EBITDA | -10.73% | -13.94% | |||
| EPS Basic | -1.33% | -7.62% | |||
| Normalized Basic EPS | -14.31% | -19.64% | |||
| EPS Diluted | -1.33% | -7.62% | |||
| Normalized Diluted EPS | -14.31% | -19.64% | |||
| Average Basic Shares Outstanding | 0.82% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.82% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||